Astromech, a start-up founded by serial entrepreneur Ben Lamm and geneticist and Harvard scholar Dr. George Church, has emerged from stealth at a two-billion dollar valuation. The company uses an evolutionary trend modeling and predictive AI engine to model biological change over time, using deep learning across species and ancestral reconstruction to identify regulatory mechanisms and selection pressures that shape biological outcomes over time. The AI-based software is also capable of projecting forward-looking patterns based on observed evolutionary data. This technology could potentially be used to predict potential future scenarios for pathogen or tumor evolution under therapeutic pressure, potentially helping pharmaceutical companies lose billions of dollars when new drugs are discovered late by late-stage mutations or resistance. Additionally, Astromech is exploring whether drug resistance can be treated as a predictable event, with the goal of better anticipating and modeling it earlier in the drug development process.